NurExone Secures U.S. GMP Manufacturing Partner for Exosome Therapies
Event summary
- NurExone signed a binding MOU with Made Scientific for exclusive U.S. GMP manufacturing and commercial supply of exosome therapies, targeting first batches in H1 2027.
- Made Scientific operates a 60,000-square-foot FDA and EU GMP Annex 1 compliant facility in Princeton, New Jersey.
- NurExone terminated its non-binding LOI with BioXtek to consolidate U.S. manufacturing under the Made Scientific partnership.
The big picture
NurExone's partnership with Made Scientific aligns with the broader trend of biotech companies outsourcing manufacturing to specialized CDMOs to accelerate clinical and commercial timelines. This move positions NurExone to capitalize on the growing demand for regenerative therapies, particularly in the U.S. market. The collaboration also underscores the strategic importance of scalable GMP infrastructure in the exosome therapeutics space.
What we're watching
- Execution Risk
- Whether NurExone can successfully transfer technology and initiate GMP production by H1 2027.
- Market Positioning
- How the partnership strengthens NurExone's competitive edge in the rapidly growing exosome therapeutics market.
- Regulatory Dynamics
- The pace at which Made Scientific can navigate FDA and EU GMP compliance for commercial-scale exosome production.
Related topics